ATAI

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ATAI Life Sciences (ATAI - Research Report), with a price target of $12.00. The company's shares opened today at $2.90.According to TipRanks, McCarthy is an analyst with an average return of -38.1% and a 14.47% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals.Currently, the analyst consensus on ATAI Life Sciences is a Strong Buy with an average price target of $25.25.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-atai-life-sciences-atai?utm_source=advfn.com&utm_medium=referral